Paper31270272
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.
Mestermann K and 9 others. Sci Transl Med, 2019. Cited by 461 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Papers, record 31270272. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31270272
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Dasatinib | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Receptors, Antigen, T-Cell | Major topic |
| T-Lymphocytes | Major topic |
| Animals | |
| Cytokine Release Syndrome | |
| Dexamethasone | |
| Female | |
| Humans | |
| Lymphocyte Activation | |
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | |
| Mice, SCID | |
| Phosphorylation |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH |
Source NIH RePORTER
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 31312040 | TKI-based on/off switch for CAR T cells. | https://conductscience.org/library/papers/31312040 | PubMed |
| Comment in | 31340935 | CAR T Cells: Hitting the Pause Button. | https://conductscience.org/library/papers/31340935 | PubMed |
| Comment in | 31371792 | Steering CARs in the right direction. | https://conductscience.org/library/papers/31371792 | PubMed |
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9180086 | HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. | Science | 1997 | https://conductscience.org/library/papers/9180086 | PubMed |
| 2 | 9857028 | Generation of destabilized green fluorescent protein as a transcription reporter. | J Biol Chem | 1998 | https://conductscience.org/library/papers/9857028 | PubMed |
| 3 | 29972754 | Chimeric Antigen Receptor Therapy. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29972754 | PubMed |
| 4 | 16740718 | The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. | Cancer Res | 2006 | https://conductscience.org/library/papers/16740718 | PubMed |
| 5 | 17429625 | Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. | Cancer Chemother Pharmacol | 2008 | https://conductscience.org/library/papers/17429625 | PubMed |
| 6 | 15728125 | An inducible caspase 9 safety switch for T-cell therapy. | Blood | 2005 | https://conductscience.org/library/papers/15728125 | PubMed |
| 7 | 27605551 | Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. | Sci Transl Med | 2016 | https://conductscience.org/library/papers/27605551 | PubMed |
| 8 | 30573301 | Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform. | Mol Ther | 2019 | https://conductscience.org/library/papers/30573301 | PubMed |
| 9 | 14965378 | Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. | Hum Gene Ther | 2004 | https://conductscience.org/library/papers/14965378 | PubMed |
| 10 | 26700307 | Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors. | PLoS One | 2015 | https://conductscience.org/library/papers/26700307 | PubMed |
| 11 | 30559421 | Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. | Nat Med | 2019 | https://conductscience.org/library/papers/30559421 | PubMed |
| 12 | 28541315 | Therapeutic T cell engineering. | Nature | 2017 | https://conductscience.org/library/papers/28541315 | PubMed |
| 13 | 28925994 | Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. | Nat Rev Clin Oncol | 2018 | https://conductscience.org/library/papers/28925994 | PubMed |
| 14 | 27760047 | Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. | J Clin Invest | 2016 | https://conductscience.org/library/papers/27760047 | PubMed |
| 15 | 29385376 | Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29385376 | PubMed |
| 16 | 29808007 | Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. | Nat Med | 2018 | https://conductscience.org/library/papers/29808007 | PubMed |
| 17 | 17310380 | The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. | Cancer Immunol Immunother | 2007 | https://conductscience.org/library/papers/17310380 | PubMed |
| 18 | 29808005 | CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. | Nat Med | 2018 | https://conductscience.org/library/papers/29808005 | PubMed |
| 19 | 18395492 | The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. | Clin Immunol | 2008 | https://conductscience.org/library/papers/18395492 | PubMed |
| 20 | 18420784 | Metabolism and disposition of dasatinib after oral administration to humans. | Drug Metab Dispos | 2008 | https://conductscience.org/library/papers/18420784 | PubMed |
Cited by308
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 461 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42952196 | BTK Inhibitor Ibrutinib Reduces Bispecific Antibody-Related CRS Without Undermining the Anti-Tumor Efficacy. | Cancer Sci | 2026 | https://conductscience.org/library/papers/42952196 | PubMed |
| 42921052 | When, Where, and How Much: Toward Smarter Design and Delivery of CAR T‑Cell Therapy. | ACS Bio Med Chem Au | 2026 | https://conductscience.org/library/papers/42921052 | PubMed |
| 42797493 | Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42797493 | PubMed |
| 42756481 | CAR T-cells for the treatment of CNS malignancies. | Front Immunol | 2026 | https://conductscience.org/library/papers/42756481 | PubMed |
| 42681665 | Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy. | Biomark Res | 2026 | https://conductscience.org/library/papers/42681665 | PubMed |
| 42665002 | Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach. | Prog Biomed Eng (Bristol) | 2026 | https://conductscience.org/library/papers/42665002 | PubMed |
| 42663750 | CAR-T cell therapy: potential for paediatric brain tumours-an update. | J Neurooncol | 2026 | https://conductscience.org/library/papers/42663750 | PubMed |
| 42626063 | Developing immunotherapies through glycosylation reprogramming to combat solid cancers. | Front Immunol | 2026 | https://conductscience.org/library/papers/42626063 | PubMed |
| 42582333 | Repurposing mitochondrial-targeting drugs for management of ICANS in CAR T-cell therapy: a novel steroid-sparing approach. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42582333 | PubMed |
| 42565078 | Co-delivery of lentiviral vectors and Cas9-containing virus-like particles enables rapid, scalable manufacture of gene-edited CAR T cells. | Mol Ther Adv | 2026 | https://conductscience.org/library/papers/42565078 | PubMed |
| 42555708 | Dasatinib reversibly disrupts T cell motility and activation in lymph nodes. | Sci Adv | 2026 | https://conductscience.org/library/papers/42555708 | PubMed |
| 42496998 | Leveraging Immunotherapy in Acute Myeloid Leukemia Treatment: Opportunities and Challenges. | Technol Cancer Res Treat | 2026 | https://conductscience.org/library/papers/42496998 | PubMed |
| 42488656 | CAR-T cell signaling dynamics, rational design principles and artificial intelligence for next-generation chimeric antigen receptors. | Front Immunol | 2026 | https://conductscience.org/library/papers/42488656 | PubMed |
| 42457686 | IL7-Receptor-Targeted CAR T-Cell Therapy for T-Cell Acute Lymphoblastic Leukemia. | Nat Commun | 2026 | https://conductscience.org/library/papers/42457686 | PubMed |
| 42454036 | Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology. | Front Immunol | 2026 | https://conductscience.org/library/papers/42454036 | PubMed |
| 42426348 | Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma. | Leukemia | 2026 | https://conductscience.org/library/papers/42426348 | PubMed |
| 42380645 | A bibliometric and visualized analysis of CAR-T or TCR-T in solid tumor (from 2015 to 2024). | Discov Oncol | 2026 | https://conductscience.org/library/papers/42380645 | PubMed |
| 42349018 | Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL. | Blood Adv | 2026 | https://conductscience.org/library/papers/42349018 | PubMed |
| 42204565 | Enhancing persistence while managing cytokine release syndrome to embrace next-generation CAR-T cell therapy. | J Transl Med | 2026 | https://conductscience.org/library/papers/42204565 | PubMed |
| 42129307 | Circadian engineering of in vivo CAR T cell therapy for precision oncology. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42129307 | PubMed |
Genes22
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31270272
GET https://conductscience.org/api/papers/v1/31270272/references?page=2